Immunology/ Transplantation. Epidemiology/ Genetics. Mini-Symposium The Future Face of Diabetes Care Beta- Cell Replacement vs. Technology Room: 24

Similar documents
FRIDAY, JUNE 21. Epidemiology/ Genetics. Symposium The Big Picture Genetic Architecture of Diabetes Room S 103 B

EXPERIENCE NEW HORIZONS IN DIABETES PRELIMINARY PROGRAM. scientificsessions.diabetes.org

Epidemiology/ Genetics. Immunology/ Transplantation

Immunology/ Transplantation. Epidemiology/ Genetics

CASE A2 Managing Between-meal Hypoglycemia

The Many Faces of T2DM in Long-term Care Facilities

Preliminary Program Outline

Diabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs

Common Diabetes-related Terms

American Diabetes Association Standards of Medical Care in Diabetes 2018: Latest Updates

Commonwealth Nurses Federation. Preventing NCDs: A primary health care response Risk factor No 1: Diabetes

Combining Complex Pathophysiologic Concepts: Diabetes Mellitus

American Diabetes Association Scientific Sessions Poster Presentation Guidelines. Table of Contents

Subject Index. postprandial glycemia and suppression in serum 51 recommendations 119, 120 supplementation pros and cons 118, 119

Diabetes Complications Recognition and Treatment

Endocrine System. Regulating Blood Sugar. Thursday, December 14, 17

Diabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh

Type 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone

Week 3, Lecture 5a. Pathophysiology of Diabetes. Simin Liu, MD, ScD

Individualizing Type 2 Diabetes Management. Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD

Prediabetes 101. What is it and what can I do about it? Intermountainhealthcare.org/diabetes

OLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION

Standards of Care in Diabetes What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE

DIAGNOSIS OF DIABETES NOW WHAT?

What is Diabetes Mellitus?

9.3 Stress Response and Blood Sugar

Pathogenesis of Diabetes Mellitus

Diabetes Pathophysiology and Treatment Strategies

OMED18 IS THE LARGEST LIVE. OMED is more than a conference. It is the largest gathering of osteopathic physicians In the world! OCTOBER 5 9 SAN DIEGO

What is Metabolic About Metabolic Surgery? The New ADA Recommendations

Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES

Maximizing the Role of WIC Nutritionists in Prevention of DM2 among High Risk Clients ESTHER G. SCHUSTER, MS,RD,CDE

Wayne Gravois, MD August 6, 2017

Diabetes Mellitus Type 2

Diabetes Mellitus. Disclaimer. Multimedia Health Education

Diabetes: Everything You Want to Know. LCDR Bernadine John, RN, BSN, CDE

DR HJ BODANSKY MD FRCP CONSULTANT PHYSICIAN LEEDS TEACHING HOSPITALS ASSOCIATE PROFESSOR, UNIVERSITY OF LEEDS

Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville

Note to the healthcare provider: The information is intended to familiarize you with the content of the Bayer Know Your Patient Education Materials.

Exercise Prescription in Type 1 Diabetes

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Patient Education Handouts Table of Contents 2013 General Diabetes Information Monitoring and Management

The Dual Hormonal Artificial Pancreas in Diabetes Management. Medical Innovation Day Challenge

Day at a Glance Schedule Saturday, April 22, 2017 Nutrition Across. Nutritional Nutrition

Thursday 25 October. Hall A

Physical Activity/Exercise Prescription with Diabetes

Diabetes Prevention in. Massachusetts: Prediabetes and the Diabetes Prevention Program. Diabetes Prevention and Control

Making the Connection

Welcome and Introduction

American Diabetes Association Scientific Sessions Poster Presentation and Moderated Poster Discussion eposter Theater Guidelines.

Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE

Disclosures of Interest. Publications Diabetologia Key points to emphasize

Chapter 37: Exercise Prescription in Patients with Diabetes

An Overview Of Diabetes And Endocrinology.

A Comprehensive Strategy on the Modern Management of Type 1 and Type 2 Diabetes

Endocrinology. Understanding Diabetes Mellitus

ADA UPDATE NM Diabetes Advisory Council. by: Maria J. Nape, J.D., Chair NM-ADA Community Leadership Board September 8, 2017

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE

5/16/2018. Beyond Patient Centered to Personalized Diabetes Care: Disclosures. Research Support. Advisory Panel

Coding spotlight: diabetes provider guide to coding the diagnosis and treatment of diabetes

Control of Glucose Metabolism

Diabetic medications

A Field Guide To Type 1 Diabetes By American Diabetes Association READ ONLINE

Metabolic Syndrome: What s so big about BIG?

Soliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)

New Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum

Vishwanath Pattan Endocrinology Wyoming Medical Center

The Endocrine System 2

Diabetes Mellitus. Raja Nursing Instructor. Acknowledgement: Badil 09/03/2016

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Diabetes School October 2016

Diabetes Mellitus Aeromedical Considerations. Aviation Medicine Seminar Bucharest, Romania. 11 th to 15 th November 2013

Provider Bulletin December 2018 Coding spotlight: diabetes provider guide to coding the diagnosis and treatment of diabetes

Improving quality of life through management of a complex disease

UNDERSTANDING TYPE 2 DIABETES

The Realities of Technology in Type 1 Diabetes

Personalized therapeutics in diabetes

10/27/2016. Processing in the Large Intestine. The colon of the large intestine is connected to the small intestine

Chapter 1 - General introduction.

2017 RESEARCH UPDATE A Year of Scientific Progress

Diabetes: We ve Come a Long Way, Baby! Amy Wachter, MD Christiana Care Endocrinology March 22, 2018

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus

ADDRESSING CHRONIC DISEASES

Making the Connection

MOVING ON... WITH DIABETES

Peter Stein, MD Janssen Research and Development

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption),

Breaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes

Making the Connection

STATE OF THE STATE: TYPE II DIABETES

8/5/2017. Disclosure to Participants. Learning Outcomes. Terry Compton MS, APRN, CDE. Seniors with Diabetes: Why Are They Different?

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care

I. General Considerations

Diabetes Risk Assessment and Treatment

Standards of Medical Care In Diabetes

Figure 2.1: Glucose meter

If DSME* were a pill, would you prescribe it?

CHAPTER 1. What is diabetes?

Transcription:

FRIDAY, JUNE 9 Registration Hours: 9:00 a.m.-6:30 p.m. Shop Store Hours: 9:00 a.m.-6:30 p.m. Clinical / 11:30 a.m.- 12:30 p.m. Mini- Clinical Innovation in Vision Mini- Exercise for Type 1 The Stigma of An Underappreciated Reality Mini- Provocative Therapies and Clinical Technologies Big Data, Small Data, and Type 1 Practice Redesign at the Intersection of Families, Providers, Value-Based Reimbursement, and Technology Mini- A Researcher s Guide to Exploring Genetic Data in the Type 2 Knowledge Portal Mini- The Future Face of Care Beta- Cell Replacement vs. Technology Mini- The Light and Dark Sides of Circadian Metabolic Regulation 12:45 p.m.- 1:45 p.m. Mini- Translational Science and Diabetic Foot Ulceration (DFU) The Pathway from the Biomechanics Lab to Clinical Practice Managing Diabetic Neuropathy Science or Art? Mini- International Guidelines Regarding Nutrition for Preschoolers with Type 1 What s App? Opportunities and Challenges in Mobile Technologies Mini- New Therapies for in Youth What the Future May Bring Sulfonylureas Should I Stay or Should I Go? Mini- The History of the ADA Guidelines Their Influence on the Study of and Clinical Practice in in Type 1 and Type 2 Mini- Biomarkers of Type 1 Mini- Human Islet Research Network NIH-Funded Interactive Research Network

FRIDAY, JUNE 9 (CONTINUED) Clinical / 2:00 p.m.- 4:00 p.m. Update on Cardiovascular Outcomes Trials (CVOTs) If You Build It, They Will Come But Will They Stay? Recruitment and Retention in Trials Hypoglycemia Prediction Models for Risk Stratification Prediction to Prevention Care for Older Adults mhealth Friend or Bystander in Management? Primer on for the Clinician Big Data and Generating Novel Hypotheses The Role of the Intestinal Immune System in Metabolic Disease Chemical Modulation of Beta-Cell Function 4:15 p.m.- 6:15 p.m. Urologic and Sexual Dysfunction in Prediction and Prevention of Cardiovascular Dietary Guidelines for Treatment of around the Globe What Are the Controversies, and What Do Differences in Guidelines Tell Us? (4:15 p.m.-5:15 p.m.) A Heavy Heart Metals,, and Cardiovascular Disease Outcomes SGLT2 Inhibitors Still More to Explore Obesity and Type 2 in Children What s New? Mechanistic Insights into Gene Function Can Omic and Genome-Wide Association Studies (GWAS) Reveal Therapeutic Links between Type 1 and Type 2? Molecular Regulators of Metabolism Mechanisms of Insulin Sensitivity and Insulin Secretion The Excited Beta Cell (5:15 p.m.-6:15 p.m.) Reaching an International Consensus on Standardizing Continuous Glucose Monitoring (CGM) Outcomes Aligning Clinicians, Researchers, Patients, and Regulators 6:30 p.m.- 8:30 p.m. Networking Reception San Diego Convention Center (Upper Level Outside Terrace)

SATURDAY, JUNE 10 Registration Hours: 7:00 a.m.-6:30 p.m. Shop Store Hours: 7:30 a.m.-6:15 p.m. Exhibit Hall Hours: 10:00 a.m.-4:00 p.m. Poster Hall Hours: 10:00 a.m.-6:00 p.m. Clinical / 8:00 a.m.- 10:00 a.m. Thirty-Year Anniversary of the Foot Care Interest Group The Diabetic Foot, Then and Now Targets and Pathways in Diabetic Kidney Disease (With State-of-the-Art ADA Education Recognition Program Introduction to the 2017 National Standards for Self- Management Education and Support Physiological Effects of Exercise in Humans with or Obesity (With State-of-the-Art Effects of in Pregnancy on the Developing Brain Is There a Unifying Mechanism? ADA Care Care and Research through the Ages Where Is Glucose Monitoring Taking Us? Race and Societal Influences on (With Vivian Fonseca Scholar Award Presentation) Clinical Mechanistic Links between Cancer, Obesity, and Glucagon and GLP-1 Physiology and Pharmacology Joint ADA/EASD Current Therapies Affecting the Islet GLP-1s and SGLT2s To Do or Not to Do in Type 1 Mellitus? (9:00 a.m.-10:00 a.m.) The Fate of the Affordable Care Act 10:15 a.m.- 11:15 a.m. President, Health Care & Education Address and Outstanding Educator in Award Lecture 11:30 a.m.- 12:30 p.m. Hyperbaric Oxygen Therapy for Diabetic Foot Ulcers (DFUs) Fact or Fiction? s Eating Behaviors in Type 1 The New Physical Activity/Exercise Guidelines for 11:30 a.m.- 12:30 p.m. General Poster Session Hall B 11:30 a.m.- 1:30 p.m. Moderated Poster Discussions Hall B

SATURDAY, JUNE 10 (CONTINUED) Clinical / 1:45 p.m.- 3:45 p.m., Drugs, and Heart Failure Putting Our Best Foot Forward The Latest in Diabetic Foot Research (With Roger Pecoraro Award The New Psychosocial Position Statement from the ADA Implications for Practice (With Richard R. Rubin Award Reducing Hospital Readmissions Effective Transitions Matter Overtreatment in Management Joint ADA/ISPAD Current Status of in Youth with Type 1 Into the Endocrine Bowels of Genome Editing in Islet Biology and Disease Therapies to Preserve Beta Cells in Type 1 Insulin Action and Cellular Metabolism The Good and the Bad of Glucagon Physiology and ADA Pathway to Stop Sending the Beta Cell Mixed Signals Dealing with the Rising Costs of Insulin An Active Dialogue 4:00 p.m.- 6:00 p.m. The Atherogenic Dyslipidemia Complex New Biomarkers and Therapies Beyond LDL Latest in Diabetic Neuropathy From Mouse to Man, and from Mechanisms to Potential Treatments Population Health, Affordable Care Act (ACA), and New Approaches for Dissemination/Implementation of the Prevention Program (DPP) Exercise-Regulated Molecular Transducers of Insulin Resistance Harnessing the Power of Digital Connectivity in Sickness and in Health Bariatric Surgery in Special Populations in Pregnancy The Tao to Understanding the Mechanisms (With Norbert Freinkel Award Sleep and What s the Link, and What Can We Do about It? Beta Cells Under Attack Lessons from for New- Onset Type 1 Insulin Signaling and Trafficking System-Based Approaches to Obesity Pathogenesis Central Nervous System Regulation of Metabolism Novel Islet Signaling Pathways Landscape of Therapeutic Trials in Type 2

Registration Hours: 7:30 a.m.-5:00 p.m. Shop Store Hours: 7:30 a.m.-6:45 p.m. DAY-AT-A-GLANCE SCHEDULE SUNDAY, JUNE 11 WEAR RED DAY Exhibit Hall Hours: 10:00 a.m.-4:00 p.m. Poster Hall Hours: 7:30 a.m.-6:30 p.m. Clinical / 8:00 a.m.- 10:00 a.m. (8:00 a.m.-9:00 a.m.) Inhibition of PCSK9 in Dyslipidemia Patients with 2017 Updates on Charcot Neuroarthropathy Hypoglycemia Mechanisms of Alerted Brain Function and Vascular Responses (9:00 a.m.-10:00 a.m.) New Learnings from the Results of the Liraglutide Effect and Action in Evaluation of Cardiovascular Outcome Results (LEADER) Trial NDEP Shared Decision- Making Strategies for Improvements in Patient Provider Communication Thinking and Working Outside the Box Prevention and Intervention Approaches Joint ADA/JDRF Progress towards an Artificial Pancreas Joint ADA/AACC The Role and Utility of Glycated Proteins Beyond A1C ADA Emerging Therapeutic Targets and Mechanisms of Action Translating to the Real World The Genetic Architecture of Fail The Islet Microenvironment and Type 1 Initiation Cellular and Circulating Mediators of Systemic Energy Metabolism State of the Science Molecular Transducers of Lifestyle Interventions to Health Benefits Obesity Pathogenesis and Treatment Insights from Mouse Models Aging and the Beta Cell 10:15 a.m.- 11:45 a.m. President, Medicine & Science Address and Banting Medal for Scientific Achievement Halls G-H 12:00 p.m.- 1:00 p.m. Making the Connection Male Hypogonadism, Testosterone Replacement, and s Joint Consensus Statement on the Use of Language in Why Language Matters Building Capacity in Psychosocial Care of People with Action Steps following the Release of the ADA Psychosocial Position Statement Staging Presymptomatic Type 1 Is There Enough Evidence? 12:00 p.m.- 1:00 p.m. General Poster Session/Moderated Poster Discussions Hall B 1:00 p.m.- 2:00 p.m. Break in Program

SUNDAY, JUNE 11 WEAR RED DAY (CONTINUED) Clinical / 2:15 p.m.- 4:15 p.m. Physiology of Nervous System Detection of Hypoglycemia Mechanisms and Modulators of Cardiovascular (With Edwin Bierman Award Exercise and Valid Mixed Results Heterogeneity of Responses to Nutrition Interventions Current Issues Should Continuous Glucose Monitoring Be Prescribed for People with Type 2? A Pro/Con Discussion Pharmacologic Strategies in Diverse Populations Results of the JDRF Reducing with Metformin Vascular Adverse Lesions in Type 1 (REMOVAL) International Multicenter Trial (2:15 p.m.-3:00 p.m.) Kelly West Award for Outstanding Achievement in Epidemiology Lecture Hot Topics Adaptive Autoimmunity and Type 1 Cell Signaling in the Central Nervous System as a Mediator of Disease Factors Influencing Epigenetic Plasticity in the Development of Type 2 Mellitus Beta-Cell Maturation in Pregnancy Baby, Baby, No Sugar Momma for Me 4:30 p.m.- 6:30 p.m. Joint ADA/ASN Effects of New Diabetic Treatments on Diabetic Kidney Disease Lipid Modifying Interventions and Their Consequences Patient-Reported Outcomes (PROs) Using Clinic-Based Screening and Intervention to Inform Care Using Technology to Improve Performance Outcomes and Care What s New in Insulin- Related Therapy? Global Therapeutic Challenges and Solutions in Care Hospital-Based Care and Adherence to Diabetic Care Strategies Gene Expression and Genome Regulation in Islets and Kidney Risk Factors Associated with Technical Innovations in Islet Novel Approaches Regulation of Differentiation and Metabolism in Brown Adipose Tissue Liver Fat and Metabolic Function Obesity, Gene, and Gut Interactions Stress Relief for the Islet (With State-of-the-Art Beyond Glycemic Impact

MONDAY, JUNE 12 Registration Hours: 7:30 a.m.-4:00 p.m. Shop Store Hours: 7:30 a.m.-6:45 p.m. Exhibit Hall Hours: 10:00 a.m.-2:00 p.m. Poster Hall Hours: 7:30 a.m.-2:00 p.m. Clinical / 8:00 a.m.- 10:00 a.m. Healthy Lifestyle Matters for Patients with and Kidney Disease Diabetic Retinopathy More than Meets the Eye Personalized Nutrition Nutrigenetics, Nutrigenomics Relevance to Digital Data Clinical Liability and Patient Safety Combination Therapy in Type 2 Promise Delivered? Potential Implications of the Affordable Care Act on Care From Prediction to Transition Type 1 Mellitus across Stages The Epidemiology of Basic Science and Physiology Cellular Energy Balance as a Basis for Metabolic (Dys)Regulation Obesity Pathogenesis and Treatment Insights from Human Studies The Neglected Delta Cell Pumps and Loops 10:15 a.m.- National Scientific & Health Care Achievement Awards Presentation and Outstanding Scientific Achievement Award Lecture Halls G-H 11:45 a.m. 12:00 p.m.- 1:00 p.m. 12:00 p.m.- 1:00 p.m. 1:00 p.m.- 2:00 p.m. s Patient-Centeredness in Research Methodology and Opportunities Metformin and Glyburide in Pregnancy You Say Goodbye, and I Say Hello To Screen or Not to Screen for T-Cell Specificities in Initial Disease and Recurrent Disease after Pancreas or Islet General Poster Session/Moderated Poster Discussions Hall B Break in Program

MONDAY, JUNE 12 (CONTINUED) Clinical / 2:15 p.m.- 4:15 p.m. Case Studies Case-Based Management of Neuropathies Cognitive Functioning and Decision-Making in Pairing Nutrition and Exercise in Type 1 (2:15 p.m.-3:15 p.m.) Cardiovascular Safety of Insulin Degludec vs. Insulin Glargine in Patients with Type 2 at High Risk of Cardiovascular Events (DEVOTE) Trial Results Room: Halls G-H Genetic Evidence for Causal Relationships in Conceptual Advances in Innate Immunity and Inflammation, Immunity, and Metabolism Antidiabetic Actions of Leptin in Insulin- Deficient Animal Models Hepatic Lipid and Glucose Metabolism Milestones of Beta-Cell Life Hyperglycemia and Adverse Pregnancy Outcome Follow-Up Study (HAPO FUS) Preserving the Beta-Cell Function (3:15 p.m.-4:15 p.m.) The Results of the CANVAS Program Room: Halls G-H 4:30 p.m.- 6:30 p.m. Systemic Correlates of Diabetic Retinopathy New Insights into Prevention and Treatment of Hypoglycemia Exercise-Induced Mediators of Metabolism and Type 2 Venturing Beyond the Bricks, Mortar, and Books Enhancing Care in Underserved and Low-Income Populations Novel Risk Factors for Gestational Mellitus (GDM) Even More to Think About Successes with Type 1 and Survival Type 1 Immune Intervention Trials Immunity and Inflammation as Mediators of Insulin Resistance Novel Metabolites and Mediators of Energy and Metabolic Homeostasis Pancreas Development Revisited from a Human Perspective

TUESDAY, JUNE 13 Registration Hours: 7:30 a.m.-10:30 a.m. Shop Store Hours: 7:30 a.m.-12:00 p.m. Clinical / 7:30 a.m.- 9:30 a.m. Hypoglycemia- Associated Autonomic Failure (HAAF) in Revisited Cognitive Decline Recognizing and Adapting Care Strategies Pediatric and Associated Comorbidities Technology and Automation for Inpatient Insulin Management Prediabetes Are We Missing Opportunities for Intervention and Risk Reduction? Mechanistic Role of Metabolic Markers in Insulin Action Current Issues A Modern Update of Thrifty Genes, Set Points, and Other Models of Obesity Pathogenesis Islet/Extracellular Matrix Interface 9:45 a.m.- 11:45 a.m. ADA Presidents Oral Session